• Mashup Score: 8

    an significantly lowers LDL-C levels, as shown by phase III studies, by inhibiting hepatic synthesis of proprotein convertase subtilisin kexin 9 (PCSK-9), a protein implicated in the degradation of LDL receptors. Inclisiran has the benefit of subcutaneous injection twice a year, which may reduce patient nonadherence when compared with other LDL-C reducing therapies such as statins and ezetimibe, which require daily dosing. When added on top of statins, a greater proportion of patients achieved recommended cholesterol goals. It has also demonstrated a good safety profile with few adverse effects. Summary Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Although it has been demonstrated to be effective in decreasing LDL-C, further research is n

    Tweet Tweets with this article
  • Mashup Score: 1

    Local GP leaders across the south of England have told practices not to follow the NHS’s advice to prescribe the cholesterol lowering drug inclisiran because of concerns over funding and long term safety monitoring. The pushback comes amid a drive by NHS England, which published funding guidance in April 2023,1 and local integrated care boards (ICBs) to make the drug available in primary care to help tackle cardiovascular disease. The National Institute for Health and Care Excellence (NICE) approved inclisiran—made by Novartis and marketed as Leqvio—in 2021,23 hailing it as “a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.” Administered by injection, inclisiran uses RNA interference to boost the liver’s ability to remove low density lipoprotein cholesterol (LDL-C) from the blood. However, the BMA, the Royal College of General Practitioners,45 and experts writing in The BMJ 6 have raised concerns about inclisiran being ini

    Tweet Tweets with this article
    • GP leaders advise practices not to prescribe cholesterol lowering drug #Inclisiran. Surprising advices for me #lipids #LLT https://t.co/t3eGZPMbw0

  • Mashup Score: 3

    Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.

    Tweet Tweets with this article
    • RT @SABOURETCardio: Novartis scraps UK heart attack prevention trial #inclisiran #LLT https://t.co/vWefi6Uh8P

  • Mashup Score: 0

    Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.

    Tweet Tweets with this article
    • 'Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes' https://t.co/EZcVXwR9tw #inclisiran @Medscape @Novartis